Retinal Dystrophy Rod Progressive clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Natural History of PRPF31 Mutation-Associated Retinal Dystrophy
open to eligible people ages 10 years and up
The purpose of this study is to characterize the natural history through temporal systemic evaluation of subjects identified with PRPF31 mutation-associated retinal dystrophy, also called retinitis pigmentosa type 11, or RP11. Assessments will be completed to measure and evaluate structural and functional visual changes including those impacting patient quality of life associated with this inherited retinal condition and observing how these changes evolve over time.
Our lead scientists for Retinal Dystrophy Rod Progressive research studies include Jacque Duncan, MD.